Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.68 |
| ▸ | MEN1 | O00255 | 6/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31159573 | 0.86 | MAPT (0.68) | MAPTMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL11776133 | 0.86 | ALDH1A1 (0.69) | MAPTMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL31570127 | 0.86 | ALDH1A1 (0.69) | MAPTMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL8391902 | 0.83 | MAPT (0.78) | MAPTMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL978809 | 0.83 | RAB9A (0.73) | MAPTMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL8784838 | 0.83 | RAB9A (0.69) | MAPTMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL978808 | 0.83 | RAB9A (0.73) | MAPTMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL7917452 | 0.82 | MAPK1 (0.80) | MAPTMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL5524662 | 0.82 | RAB9A (0.71) | MAPTMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL9368595 | 0.81 | MEN1 (0.67) | MAPTMEN1KMT2ASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368204-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | Salix Pharmaceuticals, Ltd | 2015-12-24 | — | — | US | disclosed |
| US-20150011564-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | SPROUT PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8722682-B2 | Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity | SPROUT PHARMACEUTICALS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2097389-B1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | BOEHRINGER INGELHEIM INT (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20110015207-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2097389-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | Boehringer Ingelheim International GmbH (DE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008074795-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1218352-B1 | BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE AND DOPAMINE RECEPTORS AFFINITY | BOEHRINGER INGELHEIM ITALIA (IT) | 2004-05-12 | — | — | EP | disclosed |
| US-6686353-B1 | PREVENTING BLOOD MONOCYTES AND LYMPHOCYTES FROM INFILTRATING TISSUE | TEIJIN INTELLECTUAL PROPERTY CENTER LIMITED (JP) | 2004-02-03 | — | — | US | disclosed |
| EP-1218352-A1 | BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE AND DOPAMINE RECEPTORS AFFINITY | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 2002-07-03 | — | — | EP | disclosed |
| EP-0914319-B1 | DIARYLALKYL CYCLIC DIAMINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | TEIJIN LTD (JP) | 2001-11-21 | — | — | EP | disclosed |
| US-6281218-B1 | USEFUL IN THE TREATMENT OF CNS DISORDERS. | INGELHEIM ITALIA S.P.A. (IT) | 2001-08-28 | — | — | US | disclosed |
| WO-2001021593-A1 | NEW BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE AND DOPAMINE RECEPTORS AFFINITY | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 2001-03-29 | — | — | WO | disclosed |
| WO-1997044329-A9 | DIARYLALKYL CYCLIC DIAMINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | — | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011564-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | HTR3B, HTR3A, HTR1E | MAPT 3196/4885MEN1 821/4885KMT2A 3350/4885 |
| US-20150368204-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | HTR3B, HTR3A, HTR1E | MAPT 3295/4885MEN1 884/4885KMT2A 3363/4885 |
| US-20110015207-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | HTR3A, HTR3B, NPSR1 | MAPT 4425/4885MEN1 922/4885KMT2A 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.